Sridharan Gururangan MD F.R.C.P (Edin)

PubMed

• 19 citations
  Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
  Ira J Dunkel, François Doz, Nicholas K Foreman, Darren Hargrave, Alvaro Lassaletta
  Neuro-Oncology. 2023-08-03
• 76 citations
  Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.
  Anthony P. Y. Liu, Kyle S. Smith, Rahul Kumar, Leena Paul, Laure Bihannic
  Cancer Cell. 2021-11-08
• 10 citations
  Accuracy of Central Neuro-Imaging Review of DIPG Compared with Histopathology in the International DIPG Registry.
  Margot A Lazow, Christine E. Fuller, Mariko DeWire, Adam Lane, Pratiti Bandopadhayay
  Neuro-Oncology. 2021-10-20

Journal Articles

• Heterogeneity Within the PF-EPN-B Ependymoma Subgroup  
  Andrew Grossbach, Vijay Ramaswamy, Benjamin Lu, Mariarita Santi, Caterina Giannini, Linda M Liau, Terri S Armstrong, Sarah Leary, Matthias A Karajannis, Kenneth Aldape..., Acta Neuropathologica
• Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation  
  Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Casanova M, Merks JH, Massimino M, Grill J, Daw NC, Navid F, Jin J, Allison DE, Br J Clin Pharmacol, 1/1/2016
• Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss  
  Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, ..., Nat Genet, 1/1/2015
• Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss  
  Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, ..., Nat Genet, 1/1/2015
• Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma  
  Nair SK, Driscoll T, Boczkowski D, Schmittling R, Reynolds R, Johnson LA, Grant G, Fuchs H, Bigner DD, Sampson JH, Gururangan S, Mitchell DA, J Neurooncol, 1/1/2015
• Prognostic marker analysis in pediatric intracranial ependymomas  
  McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE, 2nd, H..., J Neurooncol, 1/1/2015
• Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study  
  Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, G..., Childs Nerv Syst, 1/1/2015
• CNS- PENTs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity  
  Spence T, Sin-Chan P, Picard D, Barszczyk M, Hoss K, Lu M, Kim SK, Ra YS, Nakamura H et al, Acta Neuropathol, 1/20/2014
• Molecular variants and mutations in medulloblastoma  
  Schroeder K, Gururangan S, Pharmgenomics Pers Med, 1/1/2014
• Concordance between the Chang and International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma  
  Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Bronsi..., Pediatri Blood Cancer, 1/1/2014
• Evaluation of Amifostine for protection against cisplatin –induced serious hearing loss in children with treated for average-risk or high-risk medulloblastoma  
  Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panandiker AP, Merchant TE, Sri..., Neuro-Oncol, 1/1/2014
• Efficacy of bevacizumab plus irinotecan in children with recurrent low grade gliomas- A Pediatric Brain Tumor Consortium Study  
  Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar- Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S,..., Neuro-Oncol, 1/1/2014
• Clincopathologic description of three pediatric medulloblastoma cases with MLL 2/3 gene mutations  
  Lopez GY, Grant GA, Fuchs HE, Leithe LG, Gururangan S, Bigner DD, Yan H, McLendon RE, He Y, Neuropathol Appl Neurobiol, 1/10/2013
• Sluggish cognitive tempo in survivors of pediatric brain tumors  
  Willard VW, Hardy KK, Allen TM, Hwang EI, Gururangan S, Hostetter SA, Bonner MJ, J Neurooncol, 1/10/2013
• Neuro Oncol Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study  
  Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, ..., Neuro Oncol, 1/4/2013
• Exploratory evaluation of MR permeability with 18F-FDG-PET mapping in pediatric brain tumors: A report from the Pediatric Brain Tumor Consortium  
  Zukotynski KA, Fahey FH, Vajapeyam S, Ng SS, Kocak M, Gururangan S, Kun LE, Poussaint TY, J Nucl Med, 1/1/2013
• Recurrence patterns across medulloblatoma subgroups: an integrated clinical and molecular analysis  
  Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schuller U, Gururangan S, Lancet Oncol, 1/1/2013
• Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas  
  Kilburn LB, Kocak M, Schaedeli Stark F, Meneses-Lorente G, Brownstein C, Hussain S, Chintagumpala M, Thompson PA, Gururangan S, Banerjee A, Paulino AC, Kun L, Boyett J..., Neuro Oncol, 1/1/2013
• Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis  
  Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schüller U, Gururangan S, et al, Lancet Oncol, 1/1/2013
• A phase I pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study  
  Blaney SM, Tagen M, Onar-Thomas A, berg SL, Gururangan S, Socrsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C, Pediatr Blood Cancer, 1/1/2013
• A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study  
  Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran M, Kun L, Boyett J, Stewart C, Pediatric Blood and Cancer, 1/1/2013
• Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve recurrent glioblastoma  
  Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon II JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS, J Neurooncol, 1/1/2012
• Phase II study of Gleevec (R) plus hydroxyurea in adults with progressive or recurrent meningioma  
  Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon II JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon R, Norfleet JA, Lipp ES, Drappatz J, Wen PY, ..., J Neurooncol, 1/1/2012
• Phase II study of Gleevec (R) plus hydroxyurea in adults with progressive or recurrent low-grade glioma  
  Reardon DA, Desjardins A, Vredenburgh JJ, Herndon II JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS, Cancer, 1/1/2012
• Piot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor...  
  Blaney SM, Kocak M, Gajjar A, Chintagumpala M, Merchant T, Kieran M, Pollack IF, Gururangan S, Geyer R, Phillips P, Mclendon RE, Packer R, Goldman S, Banerjee A, Heide..., J Neurooncol, 1/1/2012
• Join now to see all

Books/Book Chapters

• Management of CNS Tumors 
  Chapter: Childhood Brain Tumors. 
  Gururangan SEditors: Miklos Garami.Intech2011
• Late Effects of Treatment for Brain Tumors 
  Chapter: Late Effects of Chemotherapy. 
  Gururangan SEditors: Stewart Goldman and Christopher Turner.Springer2010
• Cancer of the Nervous System 
  Chapter: Primitive Neuroectodermal Tumors of the Central Nervous System. 
  Gururangan S and Friedman HSEditors: Peter McL. Black and Jay S. Loeffler.Lippincott, Williams & Wilkins2005
• Neuroradiology Clinics of North America 
  Chapter: Innovations in Design and Delivery of Chemotherapy for Brain Tumors. 
  Gururangan S, Friedman HSEditors: James Provenzale.W.B. Saunders Company2004
• Clinical Bone Marrow and Stem Cell Transplantation 
  Chapter: High-dose chemotherapy and autologous hematopoietic stem cell transplantation for malignant tumors of the central nervous system. 
  Gururangan S, Gardner S, and Finlay JLEditors: Kerry Atkinson.Cambridge University PressEdition 1st,2000
• Join now to see all

Abstracts/Posters

• A prospective phase II study to determine the efficacy of GDC 0449 (Vismodegib) in adults with recurrent medulloblastoma (MB)- a pediatric brain tumor consortium study...
  Gajjar A, Gururangan S, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Fouladi M, Takebe N, Li S, Ellison D, Curren T, Gilbertson R, Boyett J, Am Assoc Cancer Res, 1/1/2013
• Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average risk or high risk medulloblastoma.
  Gurney J G, Bass J K, Onar-Thomas Arzu, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath J A, Kellie S, Cohn R, Fisher M J, Pai-Panandiker Atmaram, ..., Proc Am Soc Clinical Oncol, 1/1/2013
• Corcordance between the Chang and the International Society of Pediatrics Oncology (SIOP) ototoxcity grading scales in medulloblastoma patients treated with cisplatin.
  Bass J K, Huang J, Onar-Thomas A, Chang K W, Bhagat S P, Chintagumpala M, Bartels U, Gururangan S, Hassel T, Heath J, McCowage G, Cohn R J, Fisher M J, Robison G, Bron..., Proc Am Soc Clinical Oncol, 1/1/2013
• Subgroup specific patterns of recurrence in medulloblastoma.
  Ramaswamy V, Remke M, Bouffet E, Shih D, Faria C, Gururangan S, McLendon RM, Schuller U, Nunes S, Dunn S, Jabado N, Ligon K, Pomeroy S, Fouladi M, Hawkins C, Tabori U,..., Pediatr Blood Cancer, 1/1/2013
• Phase I/II study of adoptive T-cell therapy (ALT) and Dendritic cell vaccination (DCV) during Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Tran...
  Gururangan S, Grant GA, Driscoll T, Archer G, Sayour EJ, Herndon II JE, Friedman HS, Kurtzberg J, Bigner DD, Sampson JH, and Mitchell DA, Pediatr Blood Cancer, 1/1/2013
• Inhibition of tumor growth in pediatric brain tumor xenografts treated with LBH589 (Panobinostat).
  Keir S, Gururangan S, Reardon D, Bigner D, Friedman H, Neuro Oncol, 1/1/2011
• Clinical pathologic description of three pediatric medulloblastoma cases with MLL2/3 gene mutations.
  He Y, Lopez G, Grant G, Fuchs H, Leithe L, Gururangan S, Bigner D, Yan H, Mclendon R, Neuro Oncol, 1/1/2011
• Adoptive cellular therapy during recovery from treatment-induced lymphopenia in pediatric patients with recurrent medulloblastoma and PNETs.
  Gururangan S, Grant G, Driscoll T, Fuchs H, Reynolds R, Nair S, Johnson L, Flores C, Bigner D, Sampson J, Mitchell D, Neuro Oncol, 1/1/2011
• Immunologic profile of patients with newly-diagnosed medulloblastoma.
  Reynolds R, Gururangan S, Grant G, Reap E, Archer G, Schmittling R, Mitchell D, Neuro Oncol, 1/1/2011
• Phase II study of panitumumab in combination with irinotecan for malignant glioma patients.
  Desjardins A, Reardon DA, Peters KB, Herndon JE II, Gururangan S, Norfleet J, Friedman HS, Vredenburgh JJ, Proc Soc Neur Oncol, 1/1/2011
• Efficacy of bevacizumab + CPT-11 in children with recurrent low-grade glioma (LGG) – A Pediatric Brain Tumor Consortium study.
  Gururangan S, Fangusaro J, Young-Poussaint T, Lesh S, Onar A, Gilbertson R, Packer R, McLendon R, Friedman HS, Boyett J, Kun L, Proc Soc Neur Oncol, 1/1/2011
• Lack of efficacy of bevacizumab + irinotecan in children with recurrent ependymoma – a Pediatric Brain Tumor Consortium study.
  Gururangan S, Fangusaro J, Poussaint TY, Onar A, Gilbertson R, Packer R, McLendon R, Friedman H, Boyett J, Proc Soc Neur Oncol, 1/1/2010
• Improved survival of older children with CNS ATRT – results of the SJMB03 study.
  Gururangan S, Panandikar AP, Broniscer A, Huang A, Kellie S, Ellison D, Gajjar A, Proc Soc Neur Oncol, 1/1/2010
• Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnos...
  Vredenburgh, JJ, Desjardins A, Reardon DA, Peters K, Herndon JE, II, Kirkpatrick J, Gururangan S, Bailey L, Friedman AH, Friedman HS, Proc Am Soc Clin Oncol, 1/1/2009
• Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.
  Sathornsumetee S, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Friedman HS, Reardon DA, Proc Am Soc Clin Oncol, 1/1/2009
• Bevacizumab plus etoposide among recurrent malignant glioma patients: phase II study final results.
  Reardon D, Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Norfleet JA, Proc Am Soc Clin Oncol, 1/1/2009
• Phase I trial of combining SCH66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J, Proc Am Soc Clin Oncol, 1/1/2009
• Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.
  Kirkpatrick JP, Vredenburgh JJ, Desjardins A, Gururangan S, Peters KB, Boulton ST, Friedman AH, Friedman HS, Reardon DA, Proc Am Soc Clin Oncol, 1/1/2009
• Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.
  Herndon J., II, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS, Proc Am Soc Clin Oncol, 1/1/2009
• A phase I study of Sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma.
  Friedman HS, Vredenburgh JJ, Desjardins A, Janney DE, Peters KB, Friedman AH, Gururangan S, Reardon DA, Proc Am Soc Clin Oncol, 1/1/2009
• A phase II study of bevacizumab plus etoposide among recurrent malignant glioma patients.
  Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman HS, Proc Soc Neur Oncol, 1/1/2009
• Sunitinib plus irinotecan for patients with recurrent malignant glioma: a phase I trial.
  Desjardins A, Vredenburgh JJ, Peters KB, Friedman AH, Gururangan S, Friedman HS, Reardon DA, Proc Soc Neur Oncol, 1/1/2009
• Vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma: a phase I study.
  Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman HS, Reardon DA, Proc Soc Neur Oncol, 1/1/2009
• Bevacizumab in combination to temozolomide and radiation therapy followed by BV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme: a phase 2 trial.
  Desjardins A, Reardon DA, Peters KB, Herndon J, Kirkpatrick J, Gururangan S, Sampson JH, Friedman AH, Friedman H, Vredenburgh JJ, Proc Soc Neur Oncol, 1/1/2009
• Symptoms of inattention in survivors of pediatric brain tumors: do survivors meet symptom criteria for ADHD?
  Hardy KK, Willard VW, Allen TM, Gururangan S, Bonner MJ, Proc Soc Neur Oncol, 1/1/2009
• Join now to see all

Lectures

• Principles of Anti-Angiogenic Therapies in Brain Tumors 
  1/1/2012
• Overview of Pediatric Brain Tumors 
  Multiple Locations, 2001, 2002, 2003, 2005, 2007, 2012 - 1/1/2012
• Anti-angiogenic Treatment in Brain Tumors 
  Los Angeles, CA - 1/1/2011
• Handling CNS Tumors 
  1/1/2011
• Low Grade Gliomas in Children 
  1/1/2011
• Introduction to Pediatric Neuro-Oncology 
  1/1/2010
• Regional and Antiangiogenic Therapies for Malignant Gliomas 
  1/1/2010
• Recurrent Medulloblastoma: Recent Advances in Treatment 
  Yokohama, Japan - 1/1/2009
• Glioma Update 
  Bangalore, India, 2009; Chennai, India, 2009 - 1/1/2009
• Clinical Trials at Duke: So What is New? 
  Barcelona, Spain - 1/1/2009
• Innovative Strategies for the Treatment of Recurrent Medulloblastoma 
  1/1/2009
• Regional Therapies in Malignant Gliomas 
  1/1/2009
• Pediatric Critical Care Issues Related to Brain Tumors 
  1/1/2008
• Brain Tumors in Neurofibromatosis 
  Durham, NC - 1/1/2008
• Recent Advances in Brain Tumors 
  1/1/2008
• Introduction to Neuro-Oncology 
  1/1/2008
• Medulloblastoma 
  1/1/2008
• Pediatric Neuro-Oncology 
  1/1/2007
• Targeted Therapies in Brain Tumors: Part II 
  1/1/2007
• Targeted Therapies in Brain Tumors: Part I 
  1/1/2007
• Pediatric Brain Tumors 
  1/1/2007
• Recent Advances in the Treatment of Brain Tumor 
  1/1/2006
• Acute and Chronic Sequelae of Brain Tumor Therapy 
  1/1/2006
• High-Dose Chemotherapy in Brain Tumors 
  Milan, Italy - 1/1/2006
• Temozolomide Resistance: Mechanisms and Strategies for Reversal 
  Vancouver, Canada - 1/1/2005
• Join now to see all